109 related articles for article (PubMed ID: 37141264)
21. Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy.
Van Woensel M; Mathivet T; Wauthoz N; Rosière R; Garg AD; Agostinis P; Mathieu V; Kiss R; Lefranc F; Boon L; Belmans J; Van Gool SW; Gerhardt H; Amighi K; De Vleeschouwer S
Sci Rep; 2017 Apr; 7(1):1217. PubMed ID: 28450700
[TBL] [Abstract][Full Text] [Related]
22. High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer.
Tang D; Yuan Z; Xue X; Lu Z; Zhang Y; Wang H; Chen M; An Y; Wei J; Zhu Y; Miao Y; Jiang K
Int J Cancer; 2012 May; 130(10):2337-48. PubMed ID: 21780106
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of novel 4β-(1,3,4-oxadiazole-2-amino)-podophyllotoxin derivatives.
Ren J; Wu L; Xin WQ; Chen X; Hu K
Bioorg Med Chem Lett; 2012 Jul; 22(14):4778-82. PubMed ID: 22687745
[TBL] [Abstract][Full Text] [Related]
24. Nanobubbles containing PD-L1 Ab and miR-424 mediated PD-L1 blockade, and its expression inhibition to enable and potentiate hepatocellular carcinoma immunotherapy in mice.
Liu Y; Xie Q; Ma Y; Lin C; Li J; Hu B; Liu C; Zhao Y
Int J Pharm; 2022 Dec; 629():122352. PubMed ID: 36374798
[TBL] [Abstract][Full Text] [Related]
25. 2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1.
Chen Z; Chen Y; Peng L; Wang X; Tang N
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028694
[TBL] [Abstract][Full Text] [Related]
26. Resveratrol exerts antitumor effects by downregulating CD8
Zhang Q; Huang H; Zheng F; Liu H; Qiu F; Chen Y; Liang CL; Dai Z
Oncoimmunology; 2020 Oct; 9(1):1829346. PubMed ID: 33150044
[TBL] [Abstract][Full Text] [Related]
27. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib.
Yang Y; Sun M; Yao W; Wang F; Li X; Wang W; Li J; Gao Z; Qiu L; You R; Yang C; Ba Q; Wang H
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179631
[TBL] [Abstract][Full Text] [Related]
28. A highly stable multifunctional aptamer for enhancing antitumor immunity against hepatocellular carcinoma by blocking dual immune checkpoints.
Du Y; Zhang D; Wang Y; Wu M; Zhang C; Zheng Y; Zheng A; Liu X
Biomater Sci; 2021 Jun; 9(11):4159-4168. PubMed ID: 33970170
[TBL] [Abstract][Full Text] [Related]
29. Fe-MnO
Huang D; Xu D; Chen W; Wu R; Wen Y; Liu A; Lin L; Lin X; Wang X
Biomed Pharmacother; 2023 May; 161():114431. PubMed ID: 36827713
[TBL] [Abstract][Full Text] [Related]
30. A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.
Yao W; Ba Q; Li X; Li H; Zhang S; Yuan Y; Wang F; Duan X; Li J; Zhang W; Wang H
EBioMedicine; 2017 Aug; 22():58-67. PubMed ID: 28754304
[TBL] [Abstract][Full Text] [Related]
31. Cancer-associated fibroblasts induce immunotherapy resistance in hepatocellular carcinoma animal model.
Yu L; Liu Q; Huo J; Wei F; Guo W
Cell Mol Biol (Noisy-le-grand); 2020 May; 66(2):36-40. PubMed ID: 32415924
[TBL] [Abstract][Full Text] [Related]
32. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
Liao J; Zeng DN; Li JZ; Hua QM; Xiao Z; He C; Mao K; Zhu LY; Chu Y; Wen WP; Zheng L; Wu Y
Hepatol Int; 2020 Jan; 14(1):80-95. PubMed ID: 31802389
[TBL] [Abstract][Full Text] [Related]
33. A Sodium Alginate-Based Multifunctional Nanoplatform for Synergistic Chemo-Immunotherapy of Hepatocellular Carcinoma.
Huang C; Xie T; Liu Y; Yan S; OuYang F; Zhang H; Lei L; He D; Wei H; Yu CY
Adv Mater; 2023 Aug; 35(33):e2301352. PubMed ID: 37216573
[TBL] [Abstract][Full Text] [Related]
34. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
35. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
[TBL] [Abstract][Full Text] [Related]
36. TOX promotes the exhaustion of antitumor CD8
Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
[TBL] [Abstract][Full Text] [Related]
37. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
38. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
39. Systematic characterization of the tumor microenvironment in Chinese patients with hepatocellular carcinoma highlights intratumoral B cells as a potential immunotherapy target.
Feng Y; Liu L; Li J; Huang J; Xie JH; Menard L; Shi Y; Zhao X; Xie S; Zang W; Tan H; Yang Z; Ni L
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34958112
[TBL] [Abstract][Full Text] [Related]
40. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
Liu D; Li K; Gong L; Fu L; Yang D
Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]